Replies to post #220223 on Biotech Values

[DewDiligence]

BMY/PFE—Eliquis grew 40%(!) YoY in 2Q18 and is now selling at an annualized rate of $6.6B. (BMY books all of the Eliquis sales, but PFE owns 60% of the worldwide profit share.)

[DewDiligence]

BMY’s I-O franchise—(Opdivo+Yervoy)—worldwide sales by indication: NSCLC 35%; melanoma 35%; RCC 20%; HNSCC 5%; other 5%. (Source: Today’s 2Q18 CC.)

[DewDiligence]

BMY 3Q18 results:

https://finance.yahoo.com/news/bristol-myers-squibb-reports-third-105900519.html

Worldwide Opdivo sales were $1.79B, +42% YoY.

Worldwide Eliquis sales were $1.58B, +28% YoY.

BMY raised 2018 non-GAAP EPS guidance to $3.80-3.90 (from prior range of $3.55-3.65).